Title  | Date  | Price |
|---|
The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
| Sep 2008 |
£1,995 |
CNS Drug Discoveries: what the future holds 2008 FULL REPORT
| Aug 2008 |
£1,795 |
MarketWatch: CNS
| Aug 2008 |
£110 |
CNS Generic Drugs: Prospects and Opportunities to 2012
| Apr 2008 |
£995 |
Commercial Insight: CNS Market Overview
Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
| Apr 2008 |
£8,000 |
Central Nervous System Depression
| Mar 2008 |
£800 |
Central Nervous System Migraine
| Mar 2008 |
£800 |
Central Nervous System Multiple Sclerosis
| Mar 2008 |
£800 |
Central Nervous System Pain
| Mar 2008 |
£800 |
Central Nervous System Parkinson Disease
| Mar 2008 |
£800 |
Central Nervous System Psychotic Disorders
| Mar 2008 |
£800 |
Central Nervous System Schizophrenia
| Mar 2008 |
£800 |
Central Nervous System Memory Impairment
| Mar 2008 |
£800 |
Central Nervous System Insomnia or Sleep Disorders
| Mar 2008 |
£800 |
Central Nervous System Headache
| Mar 2008 |
£800 |
Central Nervous System Epilepsy
| Mar 2008 |
£800 |
Central Nervous System Dementia
| Mar 2008 |
£800 |
Central Nervous System Attention Deficit Disorder with Hyperactivity
| Mar 2008 |
£800 |
Central Nervous System Anxiety
| Mar 2008 |
£800 |
Central Nervous System Alzheimer Disease
| Mar 2008 |
£800 |
Central Nervous System Seizures
| Mar 2008 |
£800 |
Central Nervous System Stroke
| Mar 2008 |
£800 |
Central Nervous System Neuropathy
| Mar 2008 |
£800 |
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022
| Oct 2007 |
£1,499 |
The CNS Market Outlook To 2012
| Oct 2007 |
£1,495 |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
| Sep 2007 |
£7,600 |
Commercial Insight: Epilepsy
Companies Committed To The Cause Will Reap The Benefits
| Sep 2007 |
£7,600 |
Commercial Insight: Migraine
Opportunities Will Exist In The Wake Of Generic Attack
| Sep 2007 |
£7,600 |
Pipeline Insight: Neuropathic Pain
Emerging Drugs Fail To Capitalize In Lucrative Market
| Sep 2007 |
£6,000 |
CNS Market Trends, 2007 to 2010
Key Market Forecasts and Growth Opportunities
| Jun 2007 |
£995 |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
| Jun 2007 |
£1,999 |
Pipeline Insight: Depression
Novel drugs to grow third-line market
| Mar 2007 |
£6,000 |
Innovations in CNS
Novel therapeutics and future R&D strategies
| Jan 2007 |
£1,495 |
Stakeholder Insight: Multiple Sclerosis
Disease-modifying efficacy and side effects guide treatment choice
| Dec 2006 |
£8,000 |
Stakeholder Insight: Alzheimer's Disease
Prescribing trends indicate that neurologists are not adhering to guidelines
| Dec 2006 |
£8,000 |
Pipeline Insight: Migraine
Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
| Dec 2006 |
£6,000 |
CNS Drug Discoveries: Sleep Disorders
| Nov 2006 |
£795 |
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD)
| Nov 2006 |
£795 |
CNS Drug Discoveries: Neurodegenerative Disorders
| Nov 2006 |
£795 |
CNS Drug Discoveries: Multiple Sclerosis
| Nov 2006 |
£795 |
CNS Drug Discoveries: Depression
| Nov 2006 |
£795 |
Pipeline Insight: Breakthrough Pain
Fast-acting players will capture majority market share
| Nov 2006 |
£6,000 |
The CNS Market Outlook to 2011
| Nov 2006 |
£1,495 |
Pipeline Insight: Epilepsy
Pipeline drugs struggle to outshine their marketed predecessors
| Oct 2006 |
£6,000 |
Global Market for Sleep-Wake Disorders, 2005-2012, The
Trends, Opportunities, and Insights in a High-Value CNS Therapy Area
| Dec 2005 |
£1,100 |
previous
